Role of Adjuvant Chemotherapy in the Treatment of Surgically Resected Pediatric Nonrhabdomyosarcomatous Soft Tissue Sarcomas: A Pediatric Oncology Group Study

Abstract

The administration of adjuvant chemotherapy according to the schedule and dosages used in our trial did not improve the outcome of children with resected NRSTS. In this study, tumor grade was the most important predictor of clinical outcome in patients with resected NRSTS, and this factor should be incorporated into the stratification of patients in future trials.

Adjuvant Radiotherapy for Pediatric and Young Adult Nonrhabdomyosarcoma Soft-Tissue Sarcoma

“…Pratt et al (10) prospectively studied the value of adjuvant chemotherapy in 81 patients with negative margins, positive margins, or gross residual disease. Those with negative margins did not undergo postoperative RT.…”

“…Pratt et al (10) prospectively reviewed the data from 81 patients with surgically resected NRSTS who were randomized to receive vincristine, dactinomycin, cyclophosphamide, and doxorubicin vs. observation between 1986 and 1992. Only patients with International Rhabdomyosarcoma Study Group II and III disease received adjuvant RT.…”

Adjuvant chemotherapy for extremity soft-tissue sarcomas in adults

“…This results in dissimilar treatments based not on different diseases but on the distinct ages of patients. Notably, for pediatric oncologists, adjuvant or neoadjuvant chemotherapy is already a standard treatment in non-rhabdo softtissue sarcomas [4][5][6].…”

Synovial sarcoma in children. A single centre experience

“…Three patients received chemotherapy according to SIOP -MMT protocols for STS (branch for non-rhabdo) [12][13][14]. Response was variable.…”